News
PLX
1.210
+0.83%
0.010
Weekly Report: what happened at PLX last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at PLX last week (0408-0412)?
Weekly Report · 04/15 11:22
Weekly Report: what happened at PLX last week (0401-0405)?
Weekly Report · 04/08 11:27
Weekly Report: what happened at PLX last week (0325-0329)?
Weekly Report · 04/01 11:24
Weekly Report: what happened at PLX last week (0318-0322)?
Weekly Report · 03/25 11:27
Weekly Report: what happened at PLX last week (0311-0315)?
Weekly Report · 03/18 11:25
Protalix BioTherapeutics Q4 GAAP EPS $(0.07) Misses $(0.03) Estimate, Sales $10.49M Beat $5.80M Estimate
Protalix BioTherapeutics reports quarterly losses of $0.07 per share and sales of $10.49 million. The company missed the analyst consensus estimate of $5.80 million by 133.33%. The company reported quarterly losses for the same period last year.
Benzinga · 03/14 10:56
Protalix BioTherapeutics GAAP EPS of $0.09 misses by $0.01, revenue of $65.49M beats by $1.54M
Seeking Alpha · 03/14 10:51
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. Reports financial results for the fiscal year ended December 31, 2023. The company received regulatory approvals of Elfabrio for the treatment of adult patients with Fabry disease. Company to host conference call and webcast today at 8:30 a.m. EDT.
PR Newswire · 03/14 10:50
Earnings Scheduled For March 14, 2024
Pharming is projected to report earnings for its fourth quarter. Dick's Sporting Goods is expected to report quarterly earnings at $3.35 per share on revenue of $817.48 million. Other companies expected to release earnings before the bell include Hello Gr, Weibo and Build-A-Bear Workshop.
Benzinga · 03/14 09:52
Earnings Preview: Protalix BioTherapeutics
Protalix BioTherapeutics is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Analysts estimate the company will report an earnings per share of $-0.03. Last quarter the company missed EPS by $0.00 and shares are down 28.64%.
Benzinga · 03/13 19:01
Protalix BioTherapeutics FY Earnings Preview
Seeking Alpha · 03/13 16:32
Notable earnings before Thursday's open
Seeking Alpha · 03/13 14:29
Weekly Report: what happened at PLX last week (0304-0308)?
Weekly Report · 03/11 11:22
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
Company to host conference call and webcast at 8:30 a.m. EDT on March 14, 2024. Protalix BioTherapeutics, Inc. Will release its financial results for the fiscal year ended December 31, 2023. Management will host a conference call with investors to discuss the financial results and provide a business update. The company is focused on the development and commercialization of recombinant therapeutic proteins.
PR Newswire · 03/07 11:50
Weekly Report: what happened at PLX last week (0226-0301)?
Weekly Report · 03/04 11:25
Weekly Report: what happened at PLX last week (0219-0223)?
Weekly Report · 02/26 11:39
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET at the New York Marriott Marquis in New York City. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins. The company will attend and present at the 2024 BIO CEO & Investor Conference.
PR Newswire · 02/23 11:50
Weekly Report: what happened at PLX last week (0212-0216)?
Weekly Report · 02/19 11:42
Weekly Report: what happened at PLX last week (0205-0209)?
Weekly Report · 02/12 11:30
More
Webull provides a variety of real-time PLX stock news. You can receive the latest news about Protalix Biother through multiple platforms. This information may help you make smarter investment decisions.
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.